Retinol-binding protein 4, fetal overgrowth and fetal growth factors.

Birth Weight Case-Control Studies China Diabetes, Gestational Female Fetal Blood / metabolism Fetal Macrosomia / metabolism Gestational Age Humans Infant, Newborn Insulin / blood Insulin-Like Growth Factor I / metabolism Insulin-Like Growth Factor II / metabolism Male Pregnancy Retinol-Binding Proteins, Plasma / metabolism

Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
04 2020
Historique:
received: 06 08 2019
accepted: 03 11 2019
revised: 31 10 2019
pubmed: 1 12 2019
medline: 16 6 2021
entrez: 1 12 2019
Statut: ppublish

Résumé

Retinol-binding protein 4 (RBP-4) is an adipokine involved in regulating insulin sensitivity which would affect fetal growth. It is unclear whether RBP-4 is associated with fetal overgrowth, and unexplored which fetal growth factor(s) may mediate the association. In the Shanghai Birth Cohort, we studied 125 pairs of larger-for-gestational-age (LGA, birth weight >90th percentile, an indicator of fetal overgrowth) and optimal-for-gestational-age (OGA, 25-75th percentiles) control infants matched by sex and gestational age. We measured cord blood concentrations of RBP-4, insulin, proinsulin, insulin-like growth factor-I (IGF-I), and IGF-II. Cord blood RBP-4 concentrations were elevated in LGA vs. OGA infants (21.9 ± 6.2 vs. 20.2 ± 5.1 µg/ml, P = 0.011), and positively correlated with birth weight z score (r = 0.19, P = 0.003), cord blood proinsulin (r = 0.21, P < 0.001), IGF-I (r = 0.24, P < 0.001), and IGF-II (r = 0.15, P = 0.016). Adjusting for maternal and neonatal characteristics, each SD increment in cord blood RBP-4 was associated with a 0.28 (0.12-0.45) increase in birth weight z score (P < 0.001). Mediation analyses showed that IGF-I could account for 31.7% of the variation in birth weight z score in association with RBP-4 (P = 0.01), while IGF-II was not an effect mediator. RBP-4 was positively associated with fetal overgrowth. IGF-I (but not IGF-II) may mediate this association.

Sections du résumé

BACKGROUND
Retinol-binding protein 4 (RBP-4) is an adipokine involved in regulating insulin sensitivity which would affect fetal growth. It is unclear whether RBP-4 is associated with fetal overgrowth, and unexplored which fetal growth factor(s) may mediate the association.
METHODS
In the Shanghai Birth Cohort, we studied 125 pairs of larger-for-gestational-age (LGA, birth weight >90th percentile, an indicator of fetal overgrowth) and optimal-for-gestational-age (OGA, 25-75th percentiles) control infants matched by sex and gestational age. We measured cord blood concentrations of RBP-4, insulin, proinsulin, insulin-like growth factor-I (IGF-I), and IGF-II.
RESULTS
Cord blood RBP-4 concentrations were elevated in LGA vs. OGA infants (21.9 ± 6.2 vs. 20.2 ± 5.1 µg/ml, P = 0.011), and positively correlated with birth weight z score (r = 0.19, P = 0.003), cord blood proinsulin (r = 0.21, P < 0.001), IGF-I (r = 0.24, P < 0.001), and IGF-II (r = 0.15, P = 0.016). Adjusting for maternal and neonatal characteristics, each SD increment in cord blood RBP-4 was associated with a 0.28 (0.12-0.45) increase in birth weight z score (P < 0.001). Mediation analyses showed that IGF-I could account for 31.7% of the variation in birth weight z score in association with RBP-4 (P = 0.01), while IGF-II was not an effect mediator.
CONCLUSIONS
RBP-4 was positively associated with fetal overgrowth. IGF-I (but not IGF-II) may mediate this association.

Identifiants

DOI: 10.1038/s41390-019-0685-0 PMID: 31785592
pubmed: 31785592
doi: 10.1038/s41390-019-0685-0
pii: 10.1038/s41390-019-0685-0
doi:

Substances chimiques

Insulin 0
RBP4 protein, human 0
Retinol-Binding Proteins, Plasma 0
Insulin-Like Growth Factor I 67763-96-6
Insulin-Like Growth Factor II 67763-97-7

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

946-951

Subventions

Organisme : CIHR
ID : 158616
Pays : Canada

Investigateurs

Xiaoming Shen (X)
Hong Huang (H)
Kun Sun (K)
Jun Zhang (J)
Weiye Wang (W)
Weiping Xu (W)
Fengxiu Ouyang (F)
Lin Zhang (L)
Fei Li (F)
Yin Huang (Y)
Jinsong Zhang (J)
Chonghuai Yan (C)
Lisong Shen (L)
Yixiao Bao (Y)
Ying Tian (Y)
Weiwei Chen (W)
Huijuan Zhang (H)
Chuanliang Tong (C)
Jian Xu (J)
Yiwen Zhang (Y)
Fang Jiang (F)
Xiaodan Yu (X)
Guangjun Yu (G)
Jinjin Chen (J)
Yu Zhang (Y)
Xiaotian Li (X)
Haidong Cheng (H)
Qinying Zhang (Q)
Tao Duan (T)
Jing Hua (J)
Hua Peng (H)

Références

Esteve, E., Ricart, W. & Fernandez-Real, J. M. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 32, S362–S367 (2009).
doi: 10.2337/dc09-S340
Zabetian-Targhi, F., Mahmoudi, M. J., Rezaei, N. & Mahmoudi, M. Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases. Adv. Nutr. 6, 748–762 (2015).
doi: 10.3945/an.115.008292
Noy, N., Li, L., Abola, M. V. & Berger, N. A. Is retinol binding protein 4 a link between adiposity and cancer? Horm. Mol. Biol. Clin. Investig. 23, 39–46 (2015).
pubmed: 26136304 pmcid: 4625546
Yang, Q. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356–362 (2005).
doi: 10.1038/nature03711
Abel, E. D. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729–733 (2001).
doi: 10.1038/35055575
Graham, T. E. et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354, 2552–2563 (2006).
doi: 10.1056/NEJMoa054862
Lin, C. C. et al. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res. Clin. Pr. 85, 24–29 (2009).
doi: 10.1016/j.diabres.2009.03.016
Solini, A., Santini, E., Madec, S., Rossi, C. & Muscelli, E. Retinol-binding protein-4 in women with untreated essential hypertension. Am. J. Hypertens. 22, 1001–1006 (2009).
doi: 10.1038/ajh.2009.116
Olszanecka-Glinianowicz, M. et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur. J. Obstet. Gynecol. Reprod. Biol. 162, 55–61 (2012).
doi: 10.1016/j.ejogrb.2012.01.026
Aeberli, I. et al. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J. Clin. Endocrinol. Metab. 92, 4359–4365 (2007).
doi: 10.1210/jc.2007-0468
Chan, T. F. et al. Increased serum retinol-binding protein 4 concentrations in women with gestational diabetes mellitus. Reprod. Sci. 14, 169–174 (2007).
doi: 10.1177/1933719106298407
Mazaki-Tovi, S. et al. Retinol-binding protein 4: a novel adipokine implicated in the genesis of LGA in the absence of gestational diabetes mellitus. J. Perinat. Med. 38, 147–155 (2010).
pubmed: 20146659 pmcid: 3426355
Rich-Edwards, J. W. et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann. Intern Med. 130, 278–284 (1999).
doi: 10.7326/0003-4819-130-4_Part_1-199902160-00005
Harder, T., Rodekamp, E., Schellong, K., Dudenhausen, J. W. & Plagemann, A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am. J. Epidemiol. 165, 849–857 (2007).
doi: 10.1093/aje/kwk071
Ogonowski, J., Miazgowski, T., Engel, K. & Celewicz, Z. Birth weight predicts the risk of gestational diabetes mellitus and pregravid obesity. Nutrition 30, 39–43 (2014).
doi: 10.1016/j.nut.2013.05.021
Zhao, Y., Wang, S. F., Mu, M. & Sheng, J. Birth weight and overweight/obesity in adults: a meta-analysis. Eur. J. Pediatr. 171, 1737–1746 (2012).
doi: 10.1007/s00431-012-1701-0
Giapros, V. et al. Serum adiponectin and leptin levels and insulin resistance in children born large for gestational age are affected by the degree of overweight. Clin. Endocrinol. 66, 353–359 (2007).
doi: 10.1111/j.1365-2265.2006.02736.x
Evagelidou, E. N. et al. Prothrombotic state, cardiovascular, and metabolic syndrome risk factors in prepubertal children born large for gestational age. Diabetes Care 33, 2468–2470 (2010).
doi: 10.2337/dc10-1190
Giacomozzi, C. et al. Retinol-binding protein 4 in neonates born small for gestational age. J. Endocrinol. Invest. 33, 218–221 (2010).
doi: 10.1007/BF03345782
Chan, T. F. et al. The positive correlation between cord serum retinol-binding protein 4 concentrations and fetal growth. Gynecol. Obstet. Invest. 72, 98–102 (2011).
doi: 10.1159/000323965
Laudes, M. et al. Human fetal adiponectin and retinol-binding protein (RBP)-4 levels in relation to birth weight and maternal obesity. Exp. Clin. Endocrinol. Diabetes 117, 146–149 (2009).
doi: 10.1055/s-0028-1100379
Zhang, J. et al. Cohort profile: the Shanghai Birth Cohort. Int J. Epidemiol. 48, 21–21g (2019).
doi: 10.1093/ije/dyy277
Zhu, L. et al. Chinese neonatal birth weight curve for different gestational age. Zhonghua Er Ke Za Zhi 53, 97–103 (2015).
pubmed: 25876683
VanderWeele, T. J. Mediation analysis: a practitioner’s guide. Annu Rev. Public Health 37, 17–32 (2016).
doi: 10.1146/annurev-publhealth-032315-021402
Langer, O. Fetal macrosomia: etiologic factors. Clin. Obstet. Gynecol. 43, 283–297 (2000).
doi: 10.1097/00003081-200006000-00006
Yao-Borengasser, A. et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J. Clin. Endocrinol. Metab. 92, 2590–2597 (2007).
doi: 10.1210/jc.2006-0816
Kotnik, P., Fischer-Posovszky, P. & Wabitsch, M. RBP4: a controversial adipokine. Eur. J. Endocrinol. 165, 703–711 (2011).
doi: 10.1530/EJE-11-0431
Gluckman, P. D. & Pinal, C. S. Regulation of fetal growth by the somatotrophic axis. J. Nutr. 133, S1741–S1746 (2003).
doi: 10.1093/jn/133.5.1741S
Luo, Z. C. et al. Maternal and fetal IGF-I and IGF-II levels, fetal growth, and gestational diabetes. J. Clin. Endocrinol. Metab. 97, 1720–1728 (2012).
doi: 10.1210/jc.2011-3296

Auteurs

Meng-Nan Yang (MN)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.
Department of Obstetrics and Gynecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, M5G 1X5, Canada.

Guang-Hui Zhang (GH)

Department of Clinical Assay Laboratory, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Kun Du (K)

Department of Clinical Assay Laboratory, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Wen-Juan Wang (WJ)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.
Department of Obstetrics and Gynecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, M5G 1X5, Canada.

Yu Dong (Y)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Hua He (H)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Huei-Chen Chiu (HC)

Department of Obstetrics and Gynecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, M5G 1X5, Canada.

Yu-Na Guo (YN)

Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200030, China.

Fengxiu Ouyang (F)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Jun Zhang (J)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China.

Xiao-Lin Hua (XL)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China. huaxiaolin_sh@163.com.
Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, 200040, China. huaxiaolin_sh@163.com.

Zhong-Cheng Luo (ZC)

Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, and Department of Obstetrics, Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China. zcluo@lunenfeld.ca.
Department of Obstetrics and Gynecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, M5G 1X5, Canada. zcluo@lunenfeld.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Mensurations corporelles › Poids › Poids de naissance › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Régions géographiques › Asie › Extrême-Orient › Chine › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète gestationnel › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Structures de l'embryon › Foetus › Sang foetal › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Macrosomie foetale › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Âge gestationnel › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Nouveau-né › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones pancréatiques › Insulines › Insuline › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Somatomédines › Facteur de croissance IGF-I › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Somatomédines › Facteur de croissance IGF-II › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Retinol-binding protein 4, fetal overgrowth...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › alpha-Globulines › Protéines plasmatiques de liaison au rétinol › Retinol-binding protein 4, fetal overgrowth...